Navigation Links
OrbusNeich's Genous™ Stent Demonstrates Most Rapid Coronary Vessel Healing Compared to Bare Metal and Drug Eluting Stents at 14 Days Post-Implantation
Date:11/9/2011

oints were the percentage of malapposed struts and the absolute thickness of neointima. The study included 40 patients with stable or unstable angina or non-sustained myocardial infarction (MI) who underwent percutaneous coronary intervention with stent implantation; a total of 44 stents were implanted. The patients were randomized into four groups with 10 patients per group, and a total of 4413 stent struts were analyzed manually.  

About Genous  

Genous is OrbusNeich's patented endothelial progenitor cell (EPC) capture technology that promotes the accelerated natural healing of the vessel wall after the implantation of blood-contact devices such as stents. The technology consists of an antibody surface coating that attracts EPCs circulating in the blood to the device to form an endothelial layer that provides protection against thrombosis and modulates restenosis.

The Genous Stent, which has been commercially available in more than 60 countries since 2005, has been proven as a safe, effective alternative to drug eluting stents and is supported by data from more than 7,000 patients in company-sponsored clinical studies. There is a growing body of evidence from multiple clinical studies that the Genous Stent is effective for patients who are non-responsive to or cannot tolerate long-term dual antiplatelet therapy.

About OrbusNeich

OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world's first pro-healing stent, the Genous Stent, as well as other stents and balloons marketed under the names of Azule™, R stent, Scoreflex™, Sapphire™, Sapphire II and Sapphire NC. Development stage products include the Combo™ Dual Therapy Stent, the only dual therapy stent to both accelerate endothelial coverage and control neo-intimal proliferation through the combination of the Geno
'/>"/>

SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Three-Year Clinical Outcomes from Use of Genous™ Stent in Large, Real-World Patient Population Demonstrate Long-Term Safety and Efficacy
2. Data Published in Circulation Journal Show OrbusNeichs Genous™ Stent Is Safe and Effective in Elderly Patients
3. Two-Year Follow-Up Data Show Outstanding Clinical Outcomes and Safety for OrbusNeichs Genous™ Stent in Patients at High Risk for Restenosis
4. OrbusNeichs Genous™ Stent Enables Early and Safe Discontinuation of Dual Antiplatelet Therapy in High-Risk Patients Requiring Nondeferrable, Non-Cardiac Surgery
5. Study Confirms that OrbusNeichs Genous™ Stent Effectively Captures Circulating Endothelial Progenitor Cells to Accelerate Re-Endothelialization and Decrease Thrombogenicity
6. OrbusNeichs Genous™ Stent is Safe and Effective in Cases Where Prolonged Dual Antiplatelet Therapy is Not Advisable as Presented at EuroPCR 2011
7. Data Published in the Journal of Interventional Cardiology Demonstrate Effectiveness and Safety of OrbusNeichs Genous™ Stent in Diabetic Patients
8. Published Data From e-HEALING Registry Demonstrate Good Clinical Outcomes With Low Incidence of Repeat Revascularization and Stent Thrombosis for OrbusNeichs Genous™ Stent
9. Safety and Efficacy of OrbusNeichs Genous™ Stent Demonstrated in High-Risk Patients with Known Contraindications for Dual Antiplatelet Therapy
10. OrbusNeich Granted Expanded U.S. Patent of Genous™ Endothelial Progenitor Cell Capture Technology
11. OrbusNeichs Genous™ Stent Shows Favorable Outcomes for Treatment of Coronary Artery Bifurcation Lesions Compared to Bare Metal Stents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... BEIJING , Dec. 24, 2014  The International Trade ... by ResMed (RMD) against BMC Medical. In a notice issued ... and found that ResMed,s patent on its humidifier was invalid. ... decision a "monumental win". "We are very excited with the ... the position that we have taken since the very beginning ...
(Date:12/24/2014)... LONDON , December 24, 2014 /PRNewswire/ ... expected to grow at an average rate of 8.1%. ... and volume. Hip, knee and spine surgeries are the ... emerging economies they have a lower penetration. Increased number ... use of composites. Non-metallic orthopedic devices have gained popularity ...
(Date:12/24/2014)... ResMed (NYSE: RMD ) today announced ... medical device manufacturer BMC Medical Co., Ltd. ... listed below infringe ResMed,s patents, and entered an order prohibiting ... the United States : , iVolve ... Willow nasal pillows mask , iVolve full face mask ...
Breaking Medicine Technology:ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2
... VIEW, Calif., Sept. 16 Based on its recent ... market, Frost & Sullivan recognizes Accelrys, Inc., with the ... Product Innovation of the Year. The company has merited ... a solution that provides, for the first time, a ...
... (LIG) (Pink Sheets: LIGA ), a Dallas-based ... cleaner and disinfectant for the masks of CPAP (continuous ... for patients suffering from sleep apnea. The ... by Jones Products Company, LLC, which is 51% owned ...
Cached Medicine Technology:Frost & Sullivan Acknowledges Accelrys for Scientific Informatics Solution 2Frost & Sullivan Acknowledges Accelrys for Scientific Informatics Solution 3Frost & Sullivan Acknowledges Accelrys for Scientific Informatics Solution 4LIG Assets, Inc. Begins Distribution and Marketing of Unique CPAP Mask Cleaner 2LIG Assets, Inc. Begins Distribution and Marketing of Unique CPAP Mask Cleaner 3
(Date:12/26/2014)... Angeles, CA (PRWEB) December 26, 2014 ... power score of 3.1 out of 5. This score ... a low level of product specialization, low switching costs ... power is reduced by the low availability of substitutes ... the world price of steel and aluminum, key inputs ...
(Date:12/26/2014)... 2014 “Many people become overwhelmed by ... claim issues and phone calls with insurance companies,” The ... featuring their free eBook on pedestrian and bicycle ... pedestrian and bicycle auto accident claims assures the injured ... of professionally handling their case while they focus on ...
(Date:12/26/2014)... Phoenix, AZ (PRWEB) December 26, 2014 ... dependable source for the best in heating, cooling ... demand for 24 hour emergency services in 2014 ... customers alike know that Arizona is known for ... contractor company that understands the intricacies and details ...
(Date:12/25/2014)... The report “Nintedanib (Colorectal Cancer) – ... the current treatment landscape, unmet needs, current pipeline ... Stivarga is a drug which is used in ... Ingelheim is developing nintedanib (BIBF-1120), an orally available ... in the US, Europe, and Japan. The drug ...
(Date:12/25/2014)... Recently, iFitDress.com, the popular online supplier of ... its new selection of black one-shoulder cocktail dresses . ... they are available at discounted prices, up to 70% off. ... last for three weeks only. You know, we have thousands ... interested in our new items can visit our website for ...
Breaking Medicine News(10 mins):Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2
... N.J., Dec. 3 Covance Inc. (NYSE:,CVD), a ... leading,humanitarian organization, announced today that they are partnering ... for,Orphans and Vulnerable Children in Rwanda. Covance will ... day care centers for,children ages two to four ...
... protect cells from the powerful, common chemotherapeutic agent doxorubicin ... the drug also can destroy the heart., We found ... cell survival in the face of doxorubicin, says Dr. ... Georgia Cancer Center. At the moment you start inactivating ...
... debate , MONDAY, Dec. 3 (HealthDay News) -- There,s ... the risk of developing multiple sclerosis (MS) in childhood, a ... investigated a possible association between the hepatitis B vaccine and ... short- or long-term risk of MS. However, the studies ...
... HARBOR, N.Y. (Mon., Dec. 3, 2007) Two ... early embryogenesis are featured in this months release of ... which are freely accessible online ( www.cshprotocols.org ), describe ... These cell-tagging techniques, combined with sophisticated imaging methods, ...
... As momentum continues to,build on the issue of ... the Pharmaceutical Care Management Association,(PCMA) today announced a ... Ph.D., Sc.D., Last year, Dr. Bootman co-chaired ... all physicians begin using e-prescribing by,2010 to help ...
... and HUNTSVILLE, Ala., Dec. 3 Operon,Biotechnologies, Eurofins ... the,Eurofins Genomics network - announced today that they ... a new worldwide leader in the competitive,custom oligonucleotide ... state of,the art high-throughput production facilities in all ...
Cached Medicine News:Health News:Covance and Care Partner on Rwanda Early Childhood Development Initiative 2Health News:Covance and Care Partner on Rwanda Early Childhood Development Initiative 3Health News:Genes identified that protect against heart damage from chemotherapy 2Health News:No Link Between Hepatitis B Shot, MS: Study 2Health News:Cold Spring Harbor Protocols features innovative methods for embryology research 2Health News:MWG and Operon Are Joining Forces 2
... new Finnpipette Focus from Thermo ... combine ergonomics with uncompromising performance. ... plate offers a custom fit ... new shorter tip cones allow ...
... The Eppendorf Reference Series 2000 Pipette is ... stroke, a compact and robust design, and ... is used to operate the measuring stroke ... tip. Product features:Eppendorf "pipette/tip" system ensures utmost ...
Inquire...
... precision, ergonomics, and value!, Comfortable ... soft non-slip, contoured handle , Finer ... plunger spring action , Completely autoclavable ... the need for recalibration , Easy-to-read ...
Medicine Products: